Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women

Lupus ◽  
2017 ◽  
Vol 26 (9) ◽  
pp. 944-951 ◽  
Author(s):  
C Mendoza-Pinto ◽  
M García-Carrasco ◽  
V Vallejo-Ruiz ◽  
S Méndez-Martínez ◽  
A Taboada-Cole ◽  
...  
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Human Papillomavirus ◽  
Lupus Erythematosus ◽  
Odds Ratio ◽  
Systemic Lupus ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
Cyclophosphamide Dose ◽  
Cumulative Prevalence

Objectives Our objective was to study the incidence, persistence and clearance of human papillomavirus infection in systemic lupus erythematosus women and assess risk factors for persistence of human papillomavirus infection. Methods We carried out a prospective, observational cohort study of 127 systemic lupus erythematosus women. Patients were evaluated at baseline and at three years. Traditional and systemic lupus erythematosus women-related disease risk factors were collected. Gynaecological evaluations and cervical cytology screening were made. Human papillomavirus detection and genotyping were made by polymerase chain reaction and linear array. Results The cumulative prevalence of human papillomavirus infection increased from 22.8% at baseline to 33.8% at three years; p = < 0.001: 20.1% of patients experienced 43 incident infections. The risk of any human papillomavirus infection was 10.1 per 1000 patient-months. At three years, 47 (88.6%) prevalent infections were cleared. Independent risk factors associated with incident human papillomavirus infection included more lifetime sexual partners (odds ratio = 1.8, 95% confidence interval = 1.11–3.0) and cumulative cyclophosphamide dose (odds ratio = 3.9, 95% confidence interval = 1.2–12.8). Conclusions In systemic lupus erythematosus women, the cumulative prevalence of human papillomavirus infection, including high risk-human papillomavirus and multiple human papillomavirus infections, may increase over time. Most persistent infections were low risk-human papillomavirus. The number of lifetime sexual partners and the cumulative cyclophosphamide dose were independently associated with incident human papillomavirus infection.

scholarly journals Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review

2010 ◽  
Vol 30 (5) ◽  
pp. 665-672 ◽  
Author(s):  
Iuri Usêda Santana ◽  
Alline do Nascimento Gomes ◽  
Leomar D’Cirqueira Lyrio ◽  
Maria Fernanda Rios Grassi ◽  
Mittermayer Barreto Santiago
Keyword(s):  
Systematic Review ◽  
Systemic Lupus Erythematosus ◽  
Human Papillomavirus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
Malignant Lesions

Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis

Lupus ◽  
2011 ◽  
Vol 21 (4) ◽  
pp. 365-372 ◽  
Author(s):  
W Rojo-Contreras ◽  
EM Olivas-Flores ◽  
JI Gamez-Nava ◽  
H Montoya-Fuentes ◽  
B Trujillo-Hernandez ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Human Papillomavirus ◽  
Lupus Erythematosus ◽  
Mexican Women ◽  
Systemic Lupus ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
Cervical Human Papillomavirus

scholarly journals Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus

2012 ◽  
Vol 33 (2) ◽  
pp. 335-340 ◽  
Author(s):  
Leomar D. C. Lyrio ◽  
Maria Fernanda R. Grassi ◽  
Iuri U. Santana ◽  
Viviana G. Olavarria ◽  
Aline do N. Gomes ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Human Papillomavirus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Human Papillomavirus Infection ◽  
Papillomavirus Infection ◽  
Cervical Human Papillomavirus

Risk of systemic lupus erythematosus in patients with human papillomavirus infection: a population-based retrospective cohort study

Lupus ◽  
2018 ◽  
Vol 27 (14) ◽  
pp. 2279-2283 ◽  
Author(s):  
L-H Shi ◽  
J-Y Huang ◽  
Y-Z Liu ◽  
J-Y Chiou ◽  
R Wu ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Human Papillomavirus ◽  
Lupus Erythematosus ◽  
Hpv Infection ◽  
Population Based ◽  
Systemic Lupus ◽  
Insurance Program ◽  
Papillomavirus Infection ◽  
Hazard Ratios ◽  
Insurance Database

Background: Viral infection contributing to systemic lupus erythematosus (SLE) development has been largely reported. However, the SLE risk in patients with human papillomavirus (HPV) infection is unknown. Methods: Data were retrieved from the Longitudinal Health Insurance Database (2000) in Taiwan. We identified 43,567 patients with HPV infection and 174,268 age- and sex-matched uninfected controls from 2002 to 2012. Individuals were followed up from index date (first date of diagnosis with HPV) until the occurrence of SLE, at the end of the study (December 2013), or when they were withdrawn from the insurance program. The incidence rate ratio (IRR) was calculated using the univariate Poisson regression. The adjusted hazard ratios (aHRs) were calculated, and sensitive and subgroups analyses were also conducted. Results: Compared with the non-HPV controls, the IRR of SLE in HPV patients was 1.52 (95% confidence interval (CI): 1.09–2.12). The risk of SLE in HPV-infected individuals was significantly high (aHR: 1.48, 95% CI: 1.06–2.06) after adjusting for age, sex, and comorbidities. Men aged between 16 and 45 years were more susceptible to developing SLE (aHR: 21.57, 95% CI: 2.52–184.60, p = 0.0051). Conclusion: Our study showed a significantly higher risk of SLE among HPV-infected patients, especially in men aged between 16 and 45 years.

THU0273 DISEASE ACTIVITY IS IMPORTANT RISK FACTORS FOR MATERNAL AND FETAL OUTCOMES DURING PREGNANCY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 363-363
Author(s):  
J. W. Kim ◽  
J. Y. Jung ◽  
H. A. Kim ◽  
C. H. Suh
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Logistic Regression ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Pregnancy Outcomes ◽  
Odds Ratio ◽  
Systemic Lupus ◽  
Steroid Dose ◽  
Adverse Pregnancy

Background:Systemic lupus erythematosus (SLE) primarily affects women of childbearing age and disease activity frequently increase during pregnancy. Patient with SLE still have markedly higher risk for obstetric complications, despite discussing reproductive planning with physicians and choosing a suitable time for pregnancy.Objectives:This study aimed to examine the frequency and risk factors of complications occurring during pregnancy for women with SLE and compare with the general obstetric population.Methods:The medical records of patients with SLE and age-matched controls at Ajou University Hospital between January 1999 and June 2019 were collected and retrospectively analyzed. Clinical features and pregnancy complications for all pregnancy-related admissions for women with and without SLE were compared. Multivariate logistic regression analysis was performed to obtain the predictor of maternal and fetal adverse outcomes.Results:During this period, we analyzed 163 pregnancies in patients with SLE and 596 pregnancies in general population. Of these, except for body mass index (BMI), no other significant differences regarding demographic characteristics were noted between the groups. Lupus patients delivered significantly earlier(37 weeks + 0 days vs. 37 weeks + 6 days, p<0.001) and experienced more stillbirth (odds ratio (OR) 12.8), pre-eclampsia (OR 4.2), preterm labor (OR 2.6), emergency cesarean section (OR 2.5) and intrauterine growth retardation (odds ratio: 2.4) than age-matched controls. Using logistic regression, thrombocytopenia, low complement levels, high proteinuria, anti-ds DNA antibody positivity and high SLE Disease Activity Index (SLEDAI) were associated with maternal and fetal complications, whereas high cumulative steroid dose after SLE onset, high median steroid dose during pregnancy and history of cyclophosphamide treatment were only correlated with maternal complications. The area under the curve for SLEDAI score of adverse pregnancy outcome was 0.726 (95% CI 0.65-0.81) and cumulative steroid dose after SLE onset and median steroid dose during pregnancy for maternal outcome were 0.658 (95% confidence interval (CI) 0.55-0.76) and 0.750 (95% CI 0.65-0.85). The optimal cut-off value for SLEDAI was 4 and cumulative and median steroid dose were 2750mg and 6mg, respectively.Conclusion:Pregnant women with SLE have a higher risk of adverse pregnancy outcomes. Pregnancies should be delayed until disease activity is well controls (SLEDAI<4) for longer than 6 months.References:[1]L-W Kwok, LS Tam, TY Zhu, et al., Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2010;20:781-791[2]E Sugawara, M Kato, Y Fugieda, et al., Pregnancy outcomes in women with rheumatic disease: a real-world observational study in Japan. Lupus 2019;28:1407-1416[3]M Clowse, M Jamison, E Myers, et al., A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol 2008;199:127.e1-127.e6Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document